Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain

JAMA Oncol. 2015 Oct;1(7):982-4. doi: 10.1001/jamaoncol.2015.1066.

Authors

Helena A Yu¹, Shaozhou K Tian², Alexander E Drilon¹, Laetitia Borsu², Gregory J Riely¹, Maria E Arcila², Marc Ladanyi³

Affiliations

¹ Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York2Department of Medicine, Weill Cornell Medical College, New York, New York.
² Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
³ Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York4Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

No abstract available

Publication types

Case Reports
Letter
Research Support, N.I.H., Extramural

MeSH terms

Adenocarcinoma / drug therapy*
Adenocarcinoma / enzymology
Adenocarcinoma / genetics*
Adenocarcinoma of Lung
Aged
Antineoplastic Agents / therapeutic use*
Biomarkers, Tumor / antagonists & inhibitors*
Biomarkers, Tumor / genetics*
Biomarkers, Tumor / metabolism
Clinical Trials, Phase I as Topic
DNA Mutational Analysis
Drug Resistance, Neoplasm / genetics*
Drug Substitution
ErbB Receptors / antagonists & inhibitors*
ErbB Receptors / genetics*
ErbB Receptors / metabolism
Female
Genetic Predisposition to Disease
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / enzymology
Lung Neoplasms / genetics*
Middle Aged
Molecular Targeted Therapy
Mutation*
Phenotype
Protein Kinase Inhibitors / therapeutic use*
Protein Structure, Tertiary
Time Factors
Treatment Outcome

Substances

Antineoplastic Agents
Biomarkers, Tumor
Protein Kinase Inhibitors
EGFR protein, human
ErbB Receptors

Associated data

ClinicalTrials.gov/NCT01802632

Grants and funding